Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant

Cancers, Free Full-Text

Tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC): a multicentre, single-arm, phase 2 trial - The Lancet Oncology

VisualAbstract: Nivolumab plus ipilimumab may be less effective in females with melanoma compared to males

Optimal Treatment Sequence for Metastatic Castration-resistant Prostate Cancer - European Urology Focus

ASCO GU 2019: Initial Results from a Phase II Study of Nivolumab plus Ipilimumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer - CheckMate 650

PSMAfore: 177Lu–PSMA-617 in Taxane-Naïve Patients With Metastatic Castration -Resistant Prostate Cancer

ASCO GU 2021 - News Archives - Onco Americas

Frontiers Phase II Study of Ipilimumab in Men With Metastatic Prostate Cancer With an Incomplete Response to Androgen Deprivation Therapy

A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer

Nivolumab plus ipilimumab, with or without enzalutamide, in AR‐V7‐expressing metastatic castration‐resistant prostate cancer: A phase‐2 nonrandomized clinical trial - Shenderov - 2021 - The Prostate - Wiley Online Library